Monopar Therapeutics (NASDAQ:MNPR) Stock Price Expected to Rise, HC Wainwright Analyst Says

Monopar Therapeutics (NASDAQ:MNPR) had its price target boosted by equities researchers at HC Wainwright from $22.00 to $40.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 26.26% from the stock’s previous close.

Several other research analysts have also commented on the stock. Piper Sandler began coverage on shares of Monopar Therapeutics in a research report on Friday, January 10th. They set an “overweight” rating and a $72.00 target price for the company. Rodman & Renshaw began coverage on Monopar Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $50.00 target price on the stock.

Monopar Therapeutics Stock Performance

Shares of NASDAQ MNPR opened at $31.68 on Wednesday. The company has a market cap of $193.25 million, a price-to-earnings ratio of -16.08 and a beta of 1.23. Monopar Therapeutics has a fifty-two week low of $1.54 and a fifty-two week high of $38.50. The business’s 50 day moving average price is $23.48 and its 200-day moving average price is $12.00.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.09. Sell-side analysts predict that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Karthik Radhakrishnan bought 1,550 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The stock was purchased at an average price of $16.25 per share, with a total value of $25,187.50. Following the completion of the acquisition, the chief financial officer now directly owns 1,550 shares of the company’s stock, valued at $25,187.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 34.90% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.